Wall Street Zen Downgrades Boston Scientific to Hold

Analysts cite concerns over price target and growth outlook for medical device company.

Mar. 31, 2026 at 5:08am

Got story updates? Submit your updates here. ›

Wall Street research firm Wall Street Zen has downgraded shares of Boston Scientific (NYSE:BSX) from a 'Buy' rating to a 'Hold' rating, citing a lower price target and concerns over the medical device company's growth outlook. The move comes as Boston Scientific faces a challenging operating environment and increased competition in key product segments.

Why it matters

Boston Scientific is a major player in the medical device industry, providing a wide range of products used in minimally invasive procedures. The company's performance is closely watched by investors as an indicator of broader trends in healthcare technology and spending. This downgrade signals potential headwinds for Boston Scientific and could impact investor sentiment around the stock.

The details

In its report, Wall Street Zen lowered its price target on Boston Scientific shares from $120 to $105, while also shifting its rating from 'Buy' to 'Hold'. The analysts cited a number of factors behind the downgrade, including increased competition, pricing pressures, and a less favorable growth outlook for some of Boston Scientific's key product lines. Several other equity research firms have also recently issued updated ratings and price targets for the company, with most maintaining a 'Buy' recommendation but lowering their price targets.

  • Wall Street Zen published its downgrade report on Saturday, March 30, 2026.
  • Boston Scientific reported its Q1 2026 earnings on Wednesday, February 4, 2026.

The players

Boston Scientific

A global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 and headquartered in Marlborough, Massachusetts.

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Boston Scientific's upcoming earnings reports and guidance to gauge the company's performance and outlook amid the competitive pressures highlighted by Wall Street Zen's downgrade.

The takeaway

This downgrade from Wall Street Zen underscores the challenges facing Boston Scientific as it navigates a dynamic medical device market with rising competition and pricing pressures. The company's ability to innovate and maintain its market position will be crucial in the quarters ahead.